HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
53.25
+0.25 (+0.47%)
At close: 4:00PM EDT

53.25 0.00 (0.00%)
After hours: 4:43PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close53.00
Open52.56
Bid53.26 x 800
Ask54.70 x 1800
Day's Range51.92 - 53.80
52 Week Range26.49 - 55.25
Volume1,169,671
Avg. Volume3,266,228
Market Cap13.749B
Beta (5Y Monthly)1.44
PE Ratio (TTM)31.62
EPS (TTM)1.68
Earnings DateJul 29, 2020 - Aug 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.31
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
    Business Wire

    Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

    Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

  • Hedge Funds Done Buying Hologic, Inc. (HOLX)?
    Insider Monkey

    Hedge Funds Done Buying Hologic, Inc. (HOLX)?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Hologic Is Trading Near Its All-Time High. Is It Still a Good Buy?
    Motley Fool

    Hologic Is Trading Near Its All-Time High. Is It Still a Good Buy?

    Hologic (NASDAQ: HOLX), after earning an emergency use authorization (EUA) for a second COVID-19 molecular test from the Food and Drug Administration on May 15, is trading just a few dollars off its all-time high of $55.25, set on Feb. 4. The question for the Marlborough, Mass. medical technology company, and for investors, is whether its stock can continue to rise. The company, which has more than 6,000 employees, said it expects to produce an average of 1 million molecular COVID-19 tests per week.

  • Larry Robbins' Firm Chips Away at Top Holdings During the 1st Quarter
    GuruFocus.com

    Larry Robbins' Firm Chips Away at Top Holdings During the 1st Quarter

    Glenview’s sells include Cigna and HCA Continue reading...

  • HOLX vs. ABMD: Which Stock Should Value Investors Buy Now?
    Zacks

    HOLX vs. ABMD: Which Stock Should Value Investors Buy Now?

    HOLX vs. ABMD: Which Stock Is the Better Value Option?

  • Moody's

    Hologic, Inc. -- Moody's announces completion of a periodic review of ratings of Hologic, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Hologic, Inc. New York, May 20, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Hologic, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Thomson Reuters StreetEvents

    Edited Transcript of HOLX earnings conference call or presentation 29-Apr-20 8:30pm GMT

    Q2 2020 Hologic Inc Earnings Call

  • Hologic's Second Molecular Test Gets EUA to Detect Coronavirus
    Zacks

    Hologic's Second Molecular Test Gets EUA to Detect Coronavirus

    Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.

  • Coronavirus update: New outbreaks reported in states that plan to reopen soon, while Trump suggests testing is ‘overrated’
    MarketWatch

    Coronavirus update: New outbreaks reported in states that plan to reopen soon, while Trump suggests testing is ‘overrated’

    The U.S. death toll from the coronavirus that causes COVID-19 rose above 87,000 on Saturday, as new outbreaks were reported from states where stay-at-home orders are set to expire and in states that never imposed them, raising concerns that the reopening of economies will spur new infections.

  • Covid Report: The Trouble With Tiny Biotech's Coronavirus Cure Claim
    Investor's Business Daily

    Covid Report: The Trouble With Tiny Biotech's Coronavirus Cure Claim

    Sorrento Therapeutics claimed Friday its experimental coronavirus treatment is a cure for Covid-19. Hologic stock advanced after it gained authorization for a second coronavirus test.

  • Braveheart Resources Inc. Receives Positive System Impact Study for Hydroelectric Reconnection at Bull River Mine Project
    Newsfile

    Braveheart Resources Inc. Receives Positive System Impact Study for Hydroelectric Reconnection at Bull River Mine Project

    Calgary, Alberta--(Newsfile Corp. - May 15, 2020) - Braveheart Resources Inc. (TSXV: BHT) ("Braveheart" or the "Company") announces that it has received a positive system impact study ("SIS") from British Columbia Hydro and Power Authority ("BCH") on the Company's planned reconnection to grid power at a proposed load of 5 MW. The SIS determined that it is technically feasible to interconnect the proposed Bull River Mine load to the BCH transmission system. ...

  • Barrons.com

    Abbott Stands By Quick Covid-19 Test After FDA Warning

    The medical device maker is issuing new advice to doctors for use of its rapid test for Covid-19 after the Food and Drug Administration warned of new data suggesting the test could return false negatives.

  • Reuters

    Hologic's latest COVID-19 test gets FDA approval for emergency use

    Hologic Inc said on Friday the U.S. Food and Drug Administration granted emergency use authorization for its COVID-19 diagnostic test that can provide initial results in about three hours and process more than 1,000 tests in 24 hours. Diagnostic test makers are rushing to offer their own kits to combat the fast-spreading new coronavirus that has killed nearly 300,000 people globally and hammered financial markets. The medical device maker, which had launched its first COVID-19 test after receiving emergency use authorization in March, said it has started distribution of the latest test and expects to produce an average of 1 million tests per week.

  • MarketWatch

    Hologic shares rise on second COVID-19 test authorization

    Shares of Hologic Inc. gained 1.9% in premarket trading on Friday after the company announced that it received its second emergency use authorization (EUA) for a COVID-19 test from the Food and Drug Administration. Hologic said it "expects to produce an average of one million tests per week." Funding from the Biomedical Advanced Research and Development Authority was used to develop the test. The company previously received an EUA for a molecular COVID-19 test in mid-March. Hologic's stock is down 1.5% year-to-date, while the S&P 500 is down 11.7%.

  • Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19
    Business Wire

    Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19

    Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19

  • Coronavirus Vaccine Progress Accelerates
    Yahoo Finance

    Coronavirus Vaccine Progress Accelerates

    Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

  • Robert Olstein's Firm Buys 4 Stocks in the 1st Quarter
    GuruFocus.com

    Robert Olstein's Firm Buys 4 Stocks in the 1st Quarter

    Firm’s top new buys include Facebook and Buffett’s conglomerate Continue reading...

  • The future of successful coronavirus response: Mass testing at work and in church and self-administered tests
    MarketWatch

    The future of successful coronavirus response: Mass testing at work and in church and self-administered tests

    There are still unanswered questions about the accuracy of some COVID-19 tests, the prevalence of antibodies among Americans, and whether those antibodies provide the kind of immunity safety net needed to protect people from future infections.

  • Hologic to Webcast Presentations at Upcoming Investor Conferences
    Business Wire

    Hologic to Webcast Presentations at Upcoming Investor Conferences

    Hologic to Webcast Presentations at Upcoming Investor Conferences

  • Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
    Zacks

    Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View

    Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.

  • The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
    Benzinga

    The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Class A Common Stock(NYSE: BIO) • Capricor Therapeutics Inc (NASDAQ: CAPR)( reacted to data that showed a 100% survival rate in COVID-19 patients treated with its CAP-1002 cell therapy) • Cue Biopharma Inc (NASDAQ: CUE) • DexCom, Inc. (NASDAQ: DXCM)(reacted to its quarterly results) • Erytech Pharma SA (NASDAQ: ERYP)(announced Fast Track Designation from the FDA for its cancer drug in pancreatic cancer) • GenMark Diagnostics, Inc (NASDAQ: GNMK) • I-Mab ADR (NASDAQ: IMAB) • Immunomedics, Inc. (NASDAQ: IMMU) • Keros Therapeutics Inc (NASDAQ: KROS) • Masimo Corporation (NASDAQ: MASI)(announced solid first-quarter results) • Mersana Therapeutics Inc (NASDAQ: MRSN) • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) • Zynex Inc. (NASDAQ: ZYXI)(announced its first-quarter results)None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Wednesday.Stocks In Focus Marker's Leukemia Drug Candidate Gets Orphan Drug Designation Marker Therapeutics, Inc. (NASDAQ: MRKR) said the FDA accorded Orphan Drug Designation to MT-401, its multi-tumor-associated antigen-specific T cell product for the treatment of patients with acute myeloid leukemia following allogenic stem cell transplant.In after-hours trading, the stock rallied 23.79% to $2.81.Evotec Unit to Work With Ology to Develop Antibodies Against Coronavirus German biopharma Evotec SE (OTC: EVOTF) said its Seattle-based subsidiary Just-Evotec Biologics has entered into a partnership with Ology Bioservices for the evaluation and analytical characterisation of antibodies against SARS-CoV-2 - the virus that causes COVID-19.The company noted this work was based on a contract awarded to Ology by the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies to develop, and manufacture monoclonal antibodies for the treatment and prevention of infections with SARS-CoV-2FDA Approves an Expanded Indication For GlaxoSmithKline's Ovarian Cancer Drug GlaxoSmithKline plc (NYSE: GSK) announced FDA approval for its sNDA for Zejula as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker statusThe stock was up 1.51% to $42.48 in pre-market trading.PDS Biotech Announces Expansion to Cancer Drug Collaboration With NCI PDS Biotechnology Corp (NASDAQ: PDSB) announced an expansion of its previously announced Cooperative Research and Development Agreement with the National Cancer Institute to include studies of PDS0103, a Versamune-based product incorporating novel mucin-1 epitopes developed by the NCI.NCI is already evaluating PDS0101 in combination with two separate immune-modulating agents - NHS-IL12 and M7824 - in a phase 2 clinical trial in advanced HPV-associated cancers.The stock was adding 2.61% to 97 cents in pre-market trading.BeiGene, IGM, Atreca To Work On Coronavirus Treatment Atreca Inc (NASDAQ: BCEL), Beigene Ltd (NASDAQ: BGNE) and IGM Biosciences Inc (NASDAQ: IGMS) announced plans to collaborate to develop novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The companies said work will commence immediately, with the financial and other terms to be finalized in the future.In pre-market trading, BeiGene was edging up 0.42% to $162.30 and Atreca was advancing 3.57% to $18.Offerings NeoGenomics, Inc. (NASDAQ: NEO) priced its proposed underwritten public offerings of 4.4 million newly issued shares at $28.50 per share. The company also said it's offering $175 million in aggregate principal amount of its 1.25% convertible senior notes due 2025.The company also said underwriters of the common stock offering are also offering 1.065 million worth of shares of NeoGenomics borrowed from third parties.View more earnings on IBBThe stock slid 4.90% to $29.50 in after-hours trading.Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced plans to offer shares of its common stock in an underwritten public offering. All the shares are being offered by the company.In pre-market trading, the stock was adding 0.27% to $18.75.Earnings Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported first-quarter revenues of $1.52 million, up from $858.44 million in the year-ago quarter. On a non-GAAP basis, earnings per share, or EPS, climbed from $1.14 to $2.56, ahead of the $1.84 per share consensus estimate. The company upwardly revised its full-year net product revenue guidance.The stock was adding 2.97% to $258.50 in pre-market trading.Hologic, Inc.'s (NASDAQ: HOLX) second-quarter revenues fell 7.6% to $756.1 million, primarily reflecting Cynosure divestiture. The company reported non-GAAP EPS of 57 cents, in line with the consensus. The company withdrew its guidance for the second quarter and full year.Separately, the company said it plans to launch a new Aptima molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther system. The company expects to begin distributing a Research Use Only version of its test next week. It also plans to apply for Emergency Use Authorization with the FDA next week and register a CE Mark for diagnostic use in Europe later in May.In pre-market trading, the stock was jumping 9.07% to $53.39.Amarin Corporation plc's (NASDAQ: AMRN) first-quarter revenues climbed 112% to $155 million. The net loss per share on a non-GAAP basis narrowed from 5 cents to 3 cents. The results trumped the consensus that called for a loss of 7 cents per share on revenues of $137.43 million.Regarding the ANDA litigation, the company said hearing could happen in the third quarter or early fourth quarter, with a ruling likely in 2020 or in early 2021.Amarin said it believes that it has a strong basis for appeal, which will be set out in its opening brief proposed for filing on May 12th.In pre-market trading, Amarin shares were rallying 3.75% to $8.57.On The Radar Earnings • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open) • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open) • Baxter International Inc (NYSE: BAX) (before the market open) • BIO-TECHNE Corp (NASDAQ: TECH) (before the market open) • Genocea Biosciences Inc (NASDAQ: GNCA) (before the market open) • Novocure Ltd (NASDAQ: NVCR) (before the market open) • Syneos Health Inc (NASDAQ: SYNH) (before the market open) • PRA Health Sciences Inc (NASDAQ: PRAH) (before the market open) • Lantheus Holdings Inc (NASDAQ: LNTH) (before the market open) • Iradimed Corp (NASDAQ: IRMD) (before the market open) • Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open) • Amgen, Inc. (NASDAQ: AMGN) (after the close) • Emergent Biosolutions Inc (NYSE: EBS) (after the close) • Insmed Incorporated (NASDAQ: INSM) (after the close) • Gilead Sciences, Inc. (NASDAQ: GILD) (after the close) • Seattle Genetics, Inc. (NASDAQ: SGEN) (after the close) • Natus Medical Inc (NASDAQ: NTUS) (after the close) • Illumina, Inc. (NASDAQ: ILMN) (after the close) • PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close) • LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close) • ResMed Inc. (NYSE: RMD) (after the close) • Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) • Silk Road Medical Inc (NASDAQ: SILK) (after the close) • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) • CareDx Inc (NASDAQ: CDNA) (after the close) • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close) • Ekso Bionics Holdings Inc (NASDAQ: EKSO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda * The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update * The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Hologic Inc (HOLX) Q1 2020 Earnings Call Transcript
    Motley Fool

    Hologic Inc (HOLX) Q1 2020 Earnings Call Transcript

    HOLX earnings call for the period ending March 31, 2020.

  • MarketWatch

    Hologic stock rallies as company beat sales views

    Shares of Hologic Inc. rose more than 6% in the extended session Wednesday after the medical technology company met Wall Street expectations for its adjusted fiscal second-quarter profit and posted sales above forecasts, saying it will emerge from the pandemic as a "stronger company." Hologic said it earned $96.3 million, or 36 cents a share, in the quarter, versus a loss of $273 million in the prior-year period. Adjusted for one-time items, the company said it earned 57 cents a share, compared with 58 cents a share a year ago. Revenue fell to $756 million from $818 million a year ago. Analysts polled by FactSet expected the company to report adjusted per-share profit of 57 cents a share on sales of $746 million. Hologic withdrew its guidance, saying the coronavirus pandemic "will to have a significant negative impact on its future revenue and operating income, especially in the third quarter of fiscal 2020," but it could not quantify the impact due to uncertainties. In a separate press release late Wednesday, Hologic said it plans to launch a new research use-only version of a test to detect the virus that causes COVID-19 to labs certified to handle them. The company said it plans to apply next week to the U.S. Food and Drug Administration for an emergency-use authorization for the test. Shares of Hologic ended the regular trading day up 0.5%.